Doxofylline
Alternative Names: ABC 12/3; ALT 07; Ansimar; DO 309; MaxiventLatest Information Update: 24 Oct 2021
At a glance
- Originator ABC
- Developer Abbott GmbH & Co. KG; ABC; Alitair Pharmaceuticals Inc; sanofi-aventis
- Class Antiasthmatics; Antitussives; Bronchodilators; Small molecules; Xanthines
- Mechanism of Action Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma; Bronchitis; Chronic obstructive pulmonary disease
- No development reported Bronchiectasis
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bronchiectasis in USA (PO)
- 14 Feb 2014 Doxofylline receives Orphan Drug status for Bronchiectasis in USA (PO)